Skip to main content
Veterinary Medicines

GALLIVAC IB88 NEO EFFERVESCENT TABLET FOR OCULONASAL SUSPENSION

Authorised
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live

Product identification

Medicine name:
GALLIVAC IB88 NEO EFFERVESCENT TABLET FOR OCULONASAL SUSPENSION
Gallivac IB88 brusetablet til okulonasal suspension
Active substance:
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live
Target species:
  • Chicken (broiler)
Route of administration:
  • Oculonasal use

Product details

Active substance and strength:
  • Avian infectious bronchitis virus, type 793/B, strain CR88121, Live
    4.00
    log 10 50% embryo infective dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Effervescent tablet
Withdrawal period by route of administration:
  • Oculonasal use
    • Chicken (broiler)
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD07
Authorisation status:
  • Valid
Authorised in:
  • Denmark
Package description:
  • Carton box of 1 blister of 10 tablets of 2 000 doses
  • Carton box of 10 blisters of 10 tablets of 1 000 doses
  • Carton box of 10 blisters of 10 tablets of 2 000 doses
  • Carton box of 1 blister of 10 tablets of 1 000 doses

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Danish Health And Medicines Authority
Authorisation number:
  • 67067
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0450/001
Concerned member states:
  • Austria
  • Bulgaria
  • Croatia
  • Cyprus
  • Denmark
  • Finland
  • Greece
  • Iceland
  • Norway
  • Slovenia
  • Sweden

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Danish (PDF)
Published on: 16/11/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."